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lar thrombotic disorder.
Case presentation: In this study, we report a 32 years old woman who suffered from undifferen-
tiated vasculitis with marked improvement on steroids and cyclophosphamide. Two years later,
hepatitis C virus infection was discovered. Decision for interferon therapy was not recommended
at this stage and the patient remained stable for the following 7 years. In January 2009, pegylated
interferon and ribavirin were started due to worsening of her hepatitis; the treatment was stopped
after 12 weeks due to the absence of any virologic response. Fourteen months later, she developed
severe uncontrolled thrombotic thrombocytopenic purpura that led eventually to her death.
Conclusion: We report this rare case of thrombotic thrombocytopenic purpura that may directly
be related to chronic HCV infection rather than to interferon therapy.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Thrombotic thrombocytopenic purpura (TTP) was ﬁrst de-
scribed in 1925 as a new disease characterized by unique path-Dokki Street, Dokki Square,
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1ological ﬁndings of hyaline thrombi in many organs [1]. A
review of 271 published cases up to 1964 deﬁned the classic
pentad of the clinical features of this disease [2]: thrombocyto-
penia, microangiopathic hemolytic anemia, neurologic symp-
toms and signs, renal function abnormalities and fever.
Although some studies distinguish between TTP and hemolytic
uremic syndrome (HUS), yet the presenting features are simi-
lar in most of the patients: thrombocytopenia and microangio-
pathic hemolytic anemia without another apparent cause and,
in many patients, neurologic and/or renal abnormalities [3].
When neurologic manifestations are dominant and acute renal
failure is minimal or absent, some consider TTP to be present.
On the other hand, when acute renal failure is dominant and
neurologic abnormalities are minimal or absent, the disease
is considered by some to represent HUS [4].uction and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
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logic demonstration of hyaline thrombi in renal biopsy. The
disease was usually looked as a fatal disease, however with
the routine use of therapeutic plasma exchange, TTP-HUS
has changed from a fatal to a curable illness in many cases.
The availability of curative treatment necessitates rapid
diagnosis and less adherence to the diagnostic criteria. At the
present time, only the presence of unexplained thrombocytope-
nia and microangiopathic hemolytic anemia is required to
establish the diagnosis of TTP-HUS and initiate treatment [5].
The pathogenesis of the disease is attributed to the accumu-
lation of the unusually large von Willebrand factor (ULVWF)
multimers that lead to platelet clumping and subsequent
microvascular thrombosis. The ULVWF multimers primarily
synthesized by vascular endothelial cells, are normally rapidly
cleaved into smaller protein units by the metalloprotease en-
zyme ADAMTS 13: A Disintegrin-like And Metalloprotease
with ThromboSpondin type 1 repeats [6]. Impairment of
ADAMTS 13 activity can be due to its hereditary deﬁciency.
However, in the majority of cases, it is related to acquired
auto-antibodies that speciﬁcally inhibit ADAMTS 13 function,
with subsequent excessive accumulation of the ULVWF and
the onset of TTP-HUS [6]. Hereby, we report a rare case of
a patient who suffered from TTP as a complication of hepatitis
C virus infection.
2. Case presentation
A 32 years old woman was ﬁrst presented to the Rheumatol-
ogy Department, Cairo University Hospitals, Egypt, in
December 2000 for a gradual onset and progressive course of
burning pain sensation affecting her hands and feet and a sub-
sequent blackish discoloration of some of her ﬁnger tips. On
examination, she was mildly hypertensive (140/90 mm Hg)Table 1 Routine laboratory parameters.
Item Result
HGB (g/dl) 12.3
WBC (cell/mm3) 13.1
Staf:Seg 1:75
Lymphocytes% 20
Platelets (/mm3) 327.000
ALT (U/L) 39
AST (U/L) 38
S. albumin (g/dl) 4.3
S. creatinine (mg/dl) 0.5
Urine analysis
 Pus cells /HPF 2
 RBC /HPF 0
 Proteins Nil
 Casts 0
Cholesterol (mg/dl) 178
Triglycerides (mg/dl) 120
HDL (mg/dl) 61
LDL (mg/dl) 137
Coagulation proﬁle
 PT (m second) 14
 PC (%) 97
 a-PTT (ms) 30
 INR 1and gangrene was seen related to the distal phalanx of her right
index, ring and little ﬁngers as well as the distal phalanx of her
left index, middle and ring ﬁngers with intact peripheral pulsa-
tions. Her complete blood count was normal apart from mild
leucocytosis. Her ESR was mildly elevated (40 mm/h), but
other lab tests including complete liver biochemical proﬁle, re-
nal proﬁle, coagulation proﬁle and urine analysis were within
normal ﬁndings as shown in Table 1. ANA was borderline
(1/40), homogenous pattern, ANCA, anti-dsDNA, rheuma-
toid factor, cryoglobulins and anticardiolipin antibodies (IgG
and IgM) were negative and lupus anticoagulant had normal
values. Arterial duplex was performed on both upper limbs
and revealed normal parameters. Abdomino-pelvic ultraso-
nography showed normal liver and kidneys.
The patient was diagnosed as undifferentiated vasculitis
and she was given three grams of methyl prednisolone on three
successive days, followed by 50 mg of oral prednisolone/day.
Intravenous cyclophosphamide pulse (750 mg), started at the
fourth day, and then monthly for a total of 6 months. The ste-
roid dose was gradually tapered to a maintenance dose of
10 mg/day. In addition, low dose aspirin and verapamil
40 mg/day were given with marked improvement of her
condition.
Two years later and during her routine follow up, her liver
enzymes were elevated (less than double fold). Serological
markers were positive for hepatitis C virus and the qualitative
PCR test conﬁrmed the diagnosis. Liver biopsy was performed
and revealed mild hepatitis C related necroinﬂammation with
no evidence of ﬁbrosis. Decision for Interferon therapy was
not recommended at this stage and the patient remained stable
and asymptomatic for the following 7 years on daily mainte-
nance therapy of 10 mg oral prednisolone and liver supportive
drugs.
In January 2009, during her routine follow up, the patient’s
lab tests showed further increase of liver enzymes. A second,
liver biopsy revealed progressive increase of the necroinﬂam-
matory and ﬁbrotic state of the liver compared to the previous
one (grade 5/18 and stage of ﬁbrosis 3/6 by modiﬁed Knodell’s
score) [7] as shown in (Table 2). Subsequently, we decided to
start interferon therapy and pretreatment quantitative PCR
was 131339 copies/ml. She received weekly pegylated Inter-
feron alpha2A combined with daily ribavirin 1000 mg/day.
However, treatment stopped at 12 weeks due to the bad re-
sponse to therapy and failure of her quantitative PCR to de-
cline to satisfactory level.
The patient was hospitalized in May 2010 for an acute on-
set of uncontrolled hypertension and rapidly rising serum cre-Table 2 Liver biopsy according to modiﬁed knodell’s score.
Item Score Result
Portal Inﬂammation (0–4) 2
Periportal Inﬂammation (0–4) 1
Lytic parenchymal Foci (0–4) 2
Conﬂuent necrosis (0–6) 0
Degree of steatosis (0–100%) 10%
Granulomas +ve or ve ve
Dysplastic changes +ve or ve –ve
Malignant Changes +ve or ve –ve
Final Score: Necroinﬂammatory (0–18) 5
Final score: stage of ﬁbrosis (0–6) 3
Figure 2 Renal biopsy stained with H&E. The red arrow points
to obsolescent part of a glomerulus. The blue arrow points to
hydropic degeneration of the tubules with evidence of tubulitis.
The black arrow points to edematous interstitium with diffuse
mild inﬁltrate mainly (lymphocytes). The yellow arrow points to
the subintimal mucoid deposits and marked thickening of the
blood vessel wall. The green arrow points to the hyaline cast
formation.
Figure 3 CT abdomen. The yellow arrows point to the normal
kidney. The red arrow points to the large perinephric hematoma.
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and she had bilateral lower limb edema. Her creatinine rose
from 1.1 to 8.1 mg/dl within few days. Her hemoglobin level
was 11.9 gm/dl and platelet count 185 · 103/mm3, with
consumed C3 (C3 = 0.7 g/L with reference normal value
0.9–1.8 g/L) and normal C4. Her ESR was 25 at ﬁrst hour.
We proceeded to high resolution CT chest that unmasked
the presence of mild bilateral pleural and pericardial effusion,
left basal focal areas of small infarctions, mild bronchiectasis
and chronic pericarditis. Echocardiography revealed mild mi-
tral and tricuspid regurgitation, dilated left atrium, mild peri-
cardial effusion and normal pulmonary artery pressure.
Abdominal ultrasonography documented the presence of mild
hepatomegaly, moderate ascites and grade II nephropathy.
To complete her assessment, renal biopsy was done. It
showed thrombi within the vessels, hydropic degeneration of
the tubules, focal glomerular atrophy with hyaline cast forma-
tion and edematous interstitium as well as diffuse cellular inﬁl-
trates (mainly lymphocytes). Renal biopsy conﬁrmed the
diagnosis thrombotic microangiopathy (TMA) (Figs. 1 and
2). Aiming to save the life of the patient, hemodialysis started
and the patient received 3 g of methyl prednisolone on three
successive days followed by one pulse of cyclophosphamide
(500 mg) on the 4th day. Few days, later her hemoglobin
dropped to 5.9 g/dl. Abdomino-pelvic ultrasonography
showed a large perinephric hematoma related to the site of
biopsy around the left kidney and extending to pelvis. CT
abdomen conﬁrmed the diagnosis (Fig. 3) and for this problem
surgical embolization was done. In spite of this regimen,
marked deterioration of the general condition was progressive.
Her laboratory tests showed a rapid progressive decline of
platelet count (from 150 · 103/mm3 to 16 · 103/mm3), marked
leucopenia (1000/mm3) and reticulocytic count up to 15.7%. A
peripheral blood ﬁlm showed large number of schistocytes.
Coomb’s test was negative while D-Dimer and FDPs were
weakly positive. Microscopic analysis of urine showed hematu-
ria (RBC > 100/HPF), pyuria (WBC> 75/HPF), proteinuria
(+++) as well as hyaline and granular casts. Plasma
exchange (plasmapheresis) was initiated, with initial good re-
sponse. Serum creatinine declined to 2 mg/dl and plateletFigure 1 Renal biopsy stained with mason trichrome stain. The
red arrow points to a thrombus within a vessel, the green arrow
points to a hyaline cast. The blue arrow points to hydropic
degeneration of the tubules with evidence of tubulitis. The black
arrow points to edematous interstitium with diffuse mild inﬁltrate
mainly (lymphocytes).count rose to 190 · 103/mm3. G-CSF was given to the patient
with subsequent increases of the TLC to 7400/mm3.
Ten days later; the patient started to develop high grade fe-
ver (40 C), septic work up failed to ﬁnd an underlying etiology
and broad spectrum antibiotics were given. HIV antibodies
were also negative. Moreover, the patient developed an attack
of hematemesis, bleeding per rectum; gastroscopy revealed a
superﬁcial gastric ulcer and another deep active duodenal ul-
cer. Hemoglobin dropped again to 4 g/dl, repeated blood
transfusion and intravenous proton pump inhibitors were in-
fused. Due to worse general condition of the patient, plasma-
pheresis was paused, and repeated plasma infusion was used.
We planned to give B-cell depletion therapy (Rituximab) after
improvement of the general condition, but unfortunately her
general condition progressively deteriorated and eventually
the patient passed away.
3. Discussion
In the current study, the diagnosis of TTP was essentially
based on the presence of: hemolytic anemia with excess schis-
110 A.E. Garf et al.tocytes and negative Coomb’s test in peripheral blood, fever
up to 40 C with a negative septic workup, thrombocytopenia,
and renal biopsy that revealed thrombi within the blood ves-
sels. Neurologic manifestations were not encountered in our
patient. Many previous studies showed that fever, neurologic
and renal involvement were not consistent in all patients, espe-
cially during the early stage of the disease. The association of
microangiopathic hemolytic anemia and unexplained throm-
bocytopenia was sufﬁcient to suspect TTP and to initiate plas-
ma therapy [5].
The clinical setting and association at presentation of 206
patients with suspected TTP-HUS collected between 1996
and 2004, from the Oklahoma TTP-HUS Registry revealed
that most cases were idiopathic (37%), followed by drug-asso-
ciated (13%), autoimmune disease (13%), infection (9%),
pregnancy/postpartum (7%), bloody diarrhea prodrome
(%6), and hematopoietic cell transplantation (4%) [8].
Although most cases of post-infectious TTP-HUS occur
after an episode of bloody diarrhea caused by Shiga toxin-pro-
ducing Escherichia coli 0157:H7 [9], rare cases have developed
this disorder after a pneumococcal infection [10]. As regard
viral infections, TTP-HUS has been reported with HIV infec-
tion and attributed to direct endothelial injury [11]. A HUS-
like syndrome has been reported with the use of high dose
valacyclovir prophylaxis (8 g/day) against cytomegalovirus
infection in patients with advanced HIV infection [12]. In the
setting of HCV infection, TTP-HUS was rarely reported, usu-
ally in relation to pegylated interferon (PEG-IFN) therapy;
one case developed suddenly at 16th week during the PEG-
IFN course, while the other one has been reported one month
after the end of a long term PEG-IFN course [13,14]. One pa-
tient with HCV-related liver cirrhosis was complicated by fetal
TTP following the development of an ADAMTS13 inhibitor
[15]. In addition, a simultaneous refractory TTP and membra-
noproliferative glomerulonephritis associated with HCV
infection and successfully treated with rituximab have been
also reported, without any apparent relation to IFN therapy
[16].
4. Conclusion
Our case is unique, there was no evidence of cirrhosis and
the duration between the end of the short course PEG-IFN
therapy and onset of TTP-HUS was more than one year;
that raises the possibility of direct implication of chronic
HCV in the pathogenesis of TTP-HUS. HCV infection itself
has been associated with multiple autoimmune phenomena.
It is possible that HCV infection can alter the immune sys-
tem response and induce anti-ADAMTS13 antibody forma-
tion leading to an episode of TTP. In addition, some
patients may have a preexisting deﬁciency or defect of
ADAMTS13 putting them at even higher risk for develop-
ment of this complication. In conclusion, we here report a
case TTP associated with chronic HCV infection, that seems
to be unrelated to interferon therapy; TTP should be consid-
ered among the extrahepatic manifestations of chronic HCV
infection.Consent
Written informed consent was obtained from the patient’s rel-
ative for publication of this Case report and any accompany-
ing images.References
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